Publications
Detailed Information
Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Shin Hye | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Kim, Se Hyun | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T11:03:55Z | - |
dc.date.available | 2020-04-27T11:03:55Z | - |
dc.date.created | 2019-06-26 | - |
dc.date.issued | 2018-08 | - |
dc.identifier.citation | Esmo Open, Vol.3 No.5, p. e000332 | - |
dc.identifier.issn | 2059-7029 | - |
dc.identifier.other | 76818 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165236 | - |
dc.description.abstract | Objectives Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose-response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cell lung cancer (NSCLC). Methods Outcomes of patients with NSCLC treated with nivolumab as a routine practice at two tertiary hospitals in Korea were retrospectively analysed. Patients who could not afford standard nivolumab treatment received low-dose nivolumab (20 or 100 mg fixed dose every 3 weeks). Others received standard dose of 3 mg/kg every 2 weeks. Progression-free survival (PFS) and overall survival (OS) were measured and compared between low-dose and standard-dose groups in overall and stratified analyses according to programmed death-ligand 1 (PD-L1) status. Results Among the 47 patients with NSCLC, 18 received low-dose nivolumab. PD-L1 positivity was observed in 13 (27.7%) patients and did not differ between the groups. During 5.2 months of follow-up, the objective response rate was 13.8% in the standard-dose group and 16.7% in the low-dose group (p=0.788). Dosing of nivolumab or PD-L1 expression did not significantly affect PFS or OS. Conclusion Low-dose nivolumab can be effective in NSCLC and is worth considering as an alternative option to reducing financial toxicity. The efficacy of low-dose nivolumab requires study. | - |
dc.language | 영어 | - |
dc.publisher | BMJ Publishing Group | - |
dc.title | Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 이종석 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1136/esmoopen-2018-000332 | - |
dc.citation.journaltitle | Esmo Open | - |
dc.identifier.wosid | 000440615600008 | - |
dc.identifier.scopusid | 2-s2.0-85052646528 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | e000332 | - |
dc.citation.volume | 3 | - |
dc.identifier.sci | 000440615600008 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | ANTI-PD-1 ANTIBODY | - |
dc.subject.keywordPlus | LIGAND 1 | - |
dc.subject.keywordPlus | PEMBROLIZUMAB | - |
dc.subject.keywordPlus | DEATH-1 | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | DOCETAXEL | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.